Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2022-12-02 Governance Information
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司章程(2022年12月修订）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (公司章程) of 奥锐特药业股份有限公司 (Aurisco Pharmaceutical Co., Ltd). It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share transfer, and other corporate governance matters. It references the Company Law of China and Securities Law, and includes detailed provisions on shareholder meetings, board of directors, supervisory board, and party organization within the company. There is no indication that this is a financial report, earnings release, or any announcement of voting results or capital changes. Instead, it is a governance document that sets out the internal rules and structure of the company. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance charter, not a brief announcement or summary.
2022-12-02 Chinese
奥锐特药业股份有限公司关于变更公司注册资本并修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from 奥锐特药业股份有限公司 regarding changes to the company's registered capital and amendments to the company's articles of association (公司章程). It details the board meeting resolutions, the increase in registered capital due to a restricted stock incentive plan, and the corresponding amendments to the articles of association. The document is a formal public announcement of these corporate governance and capital structure changes, not a full financial report or detailed management discussion. It does not contain financial statements or comprehensive financial data, nor is it a report publication announcement. The content fits the category of Share Issue/Capital Change (SHA) as it involves changes in registered capital and share capital structure.
2022-12-02 Chinese
奥锐特药业股份有限公司关于召开2022年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 third quarter earnings explanation meeting (业绩说明会), including time, place, participation method, and contact information. It references the prior release of the 2022 third quarter report but does not contain any financial data or analysis itself. The document is short (1402 characters) and serves to inform investors about the upcoming earnings call event rather than presenting the earnings report or transcript. Therefore, it is best classified as an Investor Presentation (IP) since it relates to a detailed presentation for investors focusing on financial results and interaction, rather than the earnings release (ER) or call transcript (CT) itself.
2022-11-18 Chinese
奥锐特药业股份有限公司关于公司监事收到浙江证监局警示函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a warning letter issued by the Zhejiang Securities Regulatory Bureau to a company supervisor for short-swing trading violations. It details regulatory actions and the company's response to the warning. There are no financial statements, earnings data, or report attachments. The content is a regulatory compliance announcement related to legal and supervisory matters, not a financial report or management change. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is not a report publication announcement or certification letter, but a regulatory announcement.
2022-11-09 Chinese
奥锐特药业股份有限公司关于2022年限制性股票激励计划授予结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the granting results of a 2022 restricted stock incentive plan by 奥锐特药业股份有限公司. It details the number of shares granted, the recipients, the grant date, the price, the stock source, and the impact on share capital and shareholders. It also includes information about the plan's validity, lock-up periods, and the accounting impact of the stock incentive plan. The document is relatively short (3674 characters) and is focused on the announcement of the stock incentive grant results rather than a full financial report or detailed management discussion. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through issuance of restricted stock as part of an incentive plan.
2022-11-08 Chinese
奥锐特药业股份有限公司验资报告
Audit Report / Information Classification · 95% confidence The document is titled as a '验资报告' which translates to 'Capital Verification Report' or 'Audit Report on Capital Contribution'. It details the verification of the company's increased registered capital and paid-in capital as of October 21, 2022. The document includes detailed tables of capital changes, descriptions of the capital increase process, and auditor's opinions. It is issued by a certified accounting firm and includes attachments such as bank confirmation letters and certificates. The content focuses on the audit and verification of capital changes rather than a full annual report or interim financial statements. It is not a brief announcement or a presentation but a detailed audit report on capital verification. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2022-11-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.